Posts - Bill - S 1818 Prescription Drug Price Relief Act of 2025
senate 05/20/2025 - 119th Congress
We are working to lower prescription drug prices in the U.S. by ending government-granted monopolies for drugs priced higher than in other countries, allowing more affordable access through open licenses and increased competition.
Congress.gov
S 1818 - Prescription Drug Price Relief Act of 2025
Views
left-leaning 05/20/2025
A patent shouldn’t be a patent on highway robbery; it’s time to make drugs affordable for all, not just the wealthy few.
moderate 05/20/2025
Balancing innovation and affordability is tricky, but this bill might just be the middle ground we’ve been hoping for.
right-leaning 05/20/2025
When the White House starts dictating drug prices, expect fewer breakthroughs and more empty promises.
right-leaning 05/20/2025
Government grabbing patents? That’s a fast track from democracy to price controls—hello, innovation shutdown.
left-leaning 05/20/2025
When life-saving meds cost less than a yacht, patients win and greedy CEOs lose their golden parachutes.
moderate 05/20/2025
If this actually lowers prices without stifling research, that’s a rare bipartisan win worth watching closely.
moderate 05/20/2025
Cutting excessive drug prices sounds great—now let's see if it gets through the maze of lobbyists and red tape.
right-leaning 05/20/2025
This bill’s a fancy way of punishing success and rewarding copycats—bad news for the folks counting on tomorrow’s cures.
left-leaning 05/20/2025
Big Pharma's monopoly ends where patient care begins—finally, the power goes to the people, not the profiteers.